Fortrea Holdings Inc.
Health
Performance
9.0
Risk
Sell
Buy
Curious about the Scores? Learn more.

Fortrea Holdings Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

14.01.2026
Red alert. Risk levels out of control.

Fortrea Holdings Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Fortrea Holdings Inc. do? Business model and key facts

Get the full picture of Fortrea Holdings Inc.: what it builds, where it operates, and how it makes money.

Fortrea Holdings Inc. Profile

Sector: Healthcare

Industry: Biotechnology

Employees (FY): 15000

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.

shop
Company facts
Anshul Thakral
CEO
15000
Employees worldwide
shop
Performance
-10.44%
Last 12 months
shop
Growth
$2,70B
Revenue year
$-328.500.000
Net income
shop
Valuation
$1,44B
Market Cap
-5.08
Price/Earnings Ratio

Stocks related to Fortrea Holdings Inc.

Selected based on industry alignment and relative market positioning.

BCRX
BioCryst Pharmaceuticals, Inc.
7.17
+5.75%
5.5
Sell
Buy
BioCryst Pharmaceuticals, Inc.
IMCR
Immunocore Holdings plc
32.75
-1.15%
6.2
Sell
Buy
Immunocore Holdings plc
ARDX
Ardelyx, Inc.
7.04
+2.18%
5.9
Sell
Buy
Ardelyx, Inc.
IMTX
Immatics N.V.
9.92
+0.92%
8.4
Sell
Buy
Immatics N.V.
INVA
Innoviva, Inc.
19.76
+0.10%
4.0
Sell
Buy
Innoviva, Inc.

Fortrea Holdings Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.